Page 1 - reflections_dyslipidaemia_newsletter5_2023
P. 1
REFLECTIONS
Dyslipidaemia
Dyslipidaemia Global Newsletter #5 2023
TABLE OF CONTENTS
KEY ARTICLES
EPIDEMIOLOGY Welcome back to the Reflections Dyslipidaemia Global
Global burden of cardiovascular disease attributable Newsletter, where an international Scientific Planning
to metabolic risk factors, 1990-2019: An analysis of Committee summarizes and provides expert commentary
observational data from a 2019 Global Burden of Disease on the latest clinical and real-world evidence in the field of
Dyslipida
study. Wu S, et al. BMJ Open. 2023 May 12;13(5):e069397. dyslipidaemia. As with the previous newsletters, we invite you
Triglyceride-rich lipoprotein remnants, low-density to interact through links to short video commentaries from our
lipoproteins, and risk of coronary heart disease: A UK Biobank SPC, links to videos and resource tools, along with hyperlinks
study. Björnson E, et al. Eur Heart J. 2023 Jun 26;ehad337. doi:
10.1093/eurheartj/ehad337. Online ahead of print. to full articles for in-depth study.
PATHOPHYSIOLOGY Prof. Farnier (Chair)
High-density lipoprotein revisited: Biological functions and
clinical relevance. von Eckardstein A, et al. Eur Heart J. 2023 SCIENTIFIC PLANNING COMMITTEE
Apr 21;44(16):1394-1407.
TREATMENT
Prof. Michel Farnier Prof. Augusto Lavalle
Great debate: Lipid-lowering therapies should be guided (France) Cobo
by vascular imaging rather than by circulating biomarkers. (Argentina)
Tokgozoglu L, et al. Eur Heart J. 2023 Jul 1;44(25):2292-2304.
Association between achieved low-density lipoprotein
cholesterol levels and long-term cardiovascular and safety Prof. Miriam Sandin Prof. Lourdes Santos
outcomes: An analysis of FOURIER-OLE. Gaba P, et al. (Spain) (Philippines)
Circulation. 2023 Apr 18;147(16):1192-1203.
SPECIAL POPULATION – FAMILIAL
HYPERCHOLESTEROLAEMIA
2023 Update on European Atherosclerosis Society Prof. Ahmed Shawky Prof. Marcin Welnicki
Consensus Statement on Homozygous Familial (Egypt) (Poland)
Hypercholesterolaemia: New treatments and clinical
guidance. Cuchel M, et al. Eur Heart J. 2023 Jul
1;44(25):2277-2291.
ADDITIONAL ARTICLES OF INTEREST
EPIDEMIOLOGY
Global burden of cardiovascular disease attributable to metabolic risk factors,
1990-2019: An analysis of observational data from a 2019 Global Burden of
Disease study.
Wu S, et al. BMJ Open. 2023 May 12;13(5):e069397.
The Global Burden of Disease (GBD) 2019 study analyzed 369 diseases and injuries, 286 causes of death, and 87 risk factors from
1990 to 2019 for the world, 21 regions, and 204 countries and territories. Several secondary analyses of the GBD database have
been performed, including analysis of metabolic risk factors for ischaemic heart disease, and the effect of metabolic risk factors on
CVD in selected regions. The current analysis aimed to investigate the global burden of metabolic-attributed CVD and its association
with socioeconomic development status over the past 30 years.intensity, but was used by some patients in both treatment groups.
The primary endpoint was a three-year composite of death, MI, stroke, or coronary revascularization with a non-inferiority margin of
3.0 percentage points.
